Aim: To compare the risk of stroke, systemic thromboembolism and bleeding, in patients
initiating apixaban or acenocoumarol for the treatment of nonvalvular atrial fibrillation …

Aim: This study aimed to evaluate the risk of major bleeding among two cohorts of
nonvalvular atrial fibrillation patients newly initiating a vitamin K antagonist (VKA) or …

Background Vitamin K antagonists have been shown to prevent stroke in patients with atrial
fibrillation. However, many patients are not suitable candidates for or are unwilling to receive …

Background Scarce data comparing real-world outcomes between apixaban and vitamin K
antagonist (VKA) users with nonvalvular atrial fibrillation (NVAF) are available. We sought to …

The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major
bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to …

Background Non-vitamin K antagonist oral anticoagulants (NOACs), including apixaban, are
recommended for prevention of stroke and systemic embolism in non-valvular atrial …

The direct factor Xa inhibitor apixaban (Eliquis®) has predictable pharmacodynamics and
pharmacokinetics and does not require routine anticoagulation monitoring. This article …

Background Novel oral anticoagulants are the cornerstone of therapy for non‐valvular atrial
fibrillation patients to lower the risk of ischaemic stroke. Given the lack of head‐to‐head …

Background Patients with atrial fibrillation who are vitamin K antagonist (VKA)-naive may
have a higher risk of thrombosis and/or bleeding than VKA-experienced patients. Methods …

Purpose: To estimate the effectiveness of apixaban relative to warfarin in NVAF
anticoagulation suitable population in Argentina. Methods: A literature review was …